

高校での接触者検診におけるクオンティフェロン®-TB Gold の有用性

Use of QuantiFERON®-TB Gold to investigate tuberculosis contacts in a high school.

Higuchi K, Harada N, Mori T, Sekiya Y.

Respirology 2007 Jan; 12(1): 88-92 に掲載された論文の要旨と図表を掲載したものです。

要旨：

[目的] QuantiFERON®-TB Gold (QFT-G)の有用性を評価するために、高校での接触者検診に QFT-G を適用した。

[方法] 初発患者と同学年の生徒を、接触者検診としてツベルクリン反応(ツ反)と胸部 X 線検査によりスクリーニングした。QFT-G は、ツ反発赤径 30mm 以上の生徒に行った。

[結果] ツ反を実施した 349 人の生徒のうち、95 人がツ反発赤径 30mm 以上であった。ツ反分布は、濃厚接触者群と非濃厚接触者群とで類似していた。対照的に、QFT-G 検査を受けた 88 人のうち 4 人のみが QFT-G 陽性であり、これらのうち 3 人は濃厚接触者群であった。予防内服はこれら 4 人の QFT-G 陽性者のみに指示された。約 3 年間のツ反陽性で QFT-G 陰性であった 91 人の生徒の追跡調査より、1 人の結核発病者も出なかったことが明らかになった。

[考察] 約 3 年の追跡期間中、ツ反陽性・QFT-G 陰性の接触者が結核を発病しなかったことより、QFT-G はツ反より特異度が高いと思われる。ツ反との置き換え、あるいはツ反と QFT-G を組み合わせることは、本当に予防内服の指示が必要な対象者の数を減らす一助になるであろう。

[キーワード] Contact investigation, high school, tuberculin skin test, QuantiFERON®-TB Gold, chemoprophylaxis

補足：クオンティフェロン®-TB Gold は、日本ではクオンティフェロン®TB-2G
と呼ばれている。

連絡先：結核研究所 抗酸菌レファレンスセンター 樋口一恵




Figure 1 Distribution of TST responses according to erythema size (high school students): (a) All subjects, (b) close contacts, and (c) limited contacts.

Table 1 Antigen-specific IFN- γ production and tuberculin reaction of QuantiFERON[®]-TB Gold (QFT-G) positives

Subject	ESAT-6 (IU/mL)	CFP-10 (IU/mL)	Erythema (mm)
A	0.028	<u>6.124</u>	115
B	<u>0.830</u>	<u>1.811</u>	76
C	<u>3.043</u>	-0.006	74
D	<u>2.129</u>	-0.001	36

The cut-off value for QFT-G positivity is 0.35 IU/mL of IFN- γ production (ESAT-6 or CFP-10). Underlined numbers represent positive for the QFT-G-test.

- 1 Ministry of Health, Labor and Welfare (ed). Statistics of tuberculosis 2005. Japanese Anti-Tuberculosis Association, Tokyo, Japan, 2005. (in Japanese)
- 2 Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test. *Clin. Infect. Dis.* 1993; **17**: 968-75.
- 3 Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. *Lancet* 2000; **356**: 1099–104.
- 4 Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection with an interferon-gamma based assay using new antigens. *Am. J. Respir. Crit. Care Med.* 2004; **170**: 59-64.
- 5 Harada N, Mori T, Shishido S, Higuchi K, Sekiya Y. Usefulness of a novel diagnostic method of tuberculosis infection, QuantiFERON®TB-2G, in an outbreak of tuberculosis. *Kekkaku* 2004; **79**: 637-43. (in Japanese with English abstract, tables and figures)
- 6 [Brock I](#), [Weldingh K](#), [Lillebaek T](#), [Follmann F](#), [Andersen P](#). Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. *Am. J. Respir. Crit. Care Med.* 2004; **170**: 65-9.
- 7 [Funayama K](#), [Tsujiimoto A](#), [Mori M](#), et al. Usefulness of QuantiFERON TB-2G in contact investigation of a tuberculosis outbreak in a university. *Kekkaku* 2005; **80**: 527-34. (in Japanese with English abstract, tables and figures)
- 8 [Harada N](#), [Nakajima Y](#), [Higuchi K](#), [Sekiya Y](#), [Rothel J](#), [Mori T](#). Screening for tuberculosis infection using whole-blood interferon-gamma and Mantoux testing among Japanese healthcare workers. *Infect. Control Hosp. Epidemiol.* 2006; **27**: 442-8.
- 9 [Kang YA](#), [Lee HW](#), [Yoon HI](#), [Cho B](#), [Han SK](#), [Shim YS](#), [Yim JJ](#). Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. *JAMA.* 2005; 293: 2756-61.
- 10 [Pai M](#), [Gokhale K](#), [Joshi R](#), [Dogra S](#), [Kalantri S](#), [Mendiratta DK](#), [Narang](#)

- [P](#), [Daley CL](#), [Granich RM](#), [Mazurek GH](#), [Reingold AL](#), [Riley LW](#), [Colford JM Jr](#). Mycobacterium tuberculosis infection in health care workers in rural India: comparison of a whole-blood interferon gamma assay with tuberculin skin testing. [JAMA](#). 2005; 293: 2746-55.
- 11 Maeda M, Asami N, Murohashi T: Further studies on the potency of purified protein derivatives of tuberculin (PPD-s). 1st Report: Comparison of the potency of three preparations of PPD. *Kekkaku* 1960; **35**: 563-66. (in Japanese)
 - 12 Kimura M, Comstock GL, Mori T. Comparison of erythema and induration as results of tuberculin tests. *Int. J. Tuberc. Lung Dis.* 2005; **9**: 853-7.
 - 13 Ewer K, Deeks J, Alvarez L, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of *Mycobacterium tuberculosis* infection in a school tuberculosis outbreak. *Lancet* 2003; **361**: 1168–73.
 - 14 Richeldi L, Ewer K, Losi M, et al. Early diagnosis of subclinical multidrug-resistant tuberculosis. *Ann. Intern. Med.* 2004; **140**: 709-13.
 - 15 Ferebee SH. Controlled chemoprophylaxis trial in tuberculosis. A general review. *Bibl. Tuberc.* 1970; **26**: 28-106.
 - 16 IUAT. Efficacy of various duration of isoniazid preventive therapy for tuberculosis: five years follow-up in the IUAT trial. *Bull. WHO* 1982; **60**: 555-64.
 - 17 ATS/CDC Statement Committee on Latent Tuberculosis Infection. Targeted tuberculin testing and treatment of latent tuberculosis infection. [MMWR Recomm. Rep.](#) 2000; **49**:1-51.
 - 18 Karalliedde S, Katugaha LP, Urugoda CG: Tuberculin response of Sri Lankan children after BCG vaccination at birth. *Tubercle* 1987; **68**: 33-8.
 - 19 Menzies R, Vissandjee B, Rocher I, St Germain Y: The booster effect in two-step tuberculin testing among young adults in Montreal. *Ann. Intern.*

- Med.* 1994; **120**: 190-8.
- 20 Mori T. A present state and control of tuberculosis. *Internal medicine* 2001; **90**: 111-5. (in Japanese)
- 21 [Wrighton-Smith P](#), [Zellweger JP](#). Direct costs of three models for the screening of latent tuberculosis infection. *Eur Respir J.* 2006 May 31; [Epub ahead of print]
- 22 [Mori T](#), [Harada N](#). Cost-effectiveness analysis of QuantiFERON-TB 2nd generation used for detection of tuberculosis infection in contact investigations. *Kekkaku.* 2005; 80: 675-86. (in Japanese with English abstract, tables and figures)
- 23 National Institute for Clinical Excellence (NICE). TUBERCULOSIS. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. (<http://www.nice.org.uk/page.aspx?o=CG033>)